The results found that the combined use of ginsenoside Rg3 and first-line chemotherapy better improved CD3+ T lymphocyte levels (P < 0.00001), CD4+ T lymphocytes (P < 0.00001), CD8+ T lymphocytes (P = 0.003), CD4+/CD8+ T lymphocyte ratio (P = 0.0006), increased natural killer cell activity (P = 0.007), restored chemotherapy-induced leukopenia, and improved the clinical efficacy of the patients (140). Here, CD4 is linked to Decreased total leukocyte count.